Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beam Therapeutics Inc. (BEAM)
USD30.67
-0.33 (-1.07%)
US NASDAQ S&P 500
Healthcare Biotechnology
Address
238 Main Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
John Evans
Website
beamtx.com
IPO
2020-02-06
CIK 1745999 ISIN US07373V1052
Description
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
News Sentiment (7d)
3 articles
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1976-07-01 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD30.67
-0.33 (-1.07%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.20
Float Shares
87.92M
Free Float %
85.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.76% | +0.09% | +15.75% | +17.90% | +45.18% | +14.54% | +74.07% | -4.74% | -52.53% | +69.33% | +69.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (27 ratings, all time)
Buy
Price Targets & DCF
Current price
30.67
Low
26.00
-15.2%
Consensus
40.83
+33.1%
Median
38.00
+23.9%
High
74.00
+141.3%
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 14 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
50.00
+63.0%
|
| Last Year | 7 |
40.86
+33.2%
|
| All Time | 17 |
48.24
+57.3%
|
Quality scores
Altman Z-Score
5.52
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+120.0% ★ Q1'26: +324.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+82.3% ★ Q1'26: +26.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-151.0% Q1'26: -412.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-26.0% Q1'26: -337.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-12.6% ★ Q1'26: -210.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.2% Q1'26: +17.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-9.82× Q1'26: -0.62× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 11 EPS Ana. |
Dec 2028 11 Rev. Ana. 10 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.0K
est: 10.0K (+140.0%)
|
51.84M
est: 11.60M (+347.0%)
|
60.92M
est: 54.19M (+12.4%)
|
377.71M
est: 352.57M (+7.1%)
|
63.52M
est: 51.41M (+23.5%)
|
139.74M
est: 35.99M (+288.3%)
|
63.91M
22.76M – 89.05M
+77.6% YoY
|
75.75M
23.08M – 104.59M
+18.5% YoY
|
126.72M
126.20M – 127.24M
+67.3% YoY
|
410.06M
166.94M – 672.47M
+223.6% YoY
|
905.00M
368.43M – 1.48B
+120.7% YoY
|
| EBITDA |
-128.03M
est: -8.8K (-1,458,375.7%)
|
-230.06M
est: -622.04M (+63.0%)
|
-324.33M
est: -270.01M (-20.1%)
|
-146.95M
est: -254.07M (+42.2%)
|
-393.64M
est: -37.05M (-962.4%)
|
-29.92M
est: -25.94M (-15.4%)
|
-46.06M
-64.18M – -16.40M
-77.6% YoY
|
-54.59M
-75.37M – -16.63M
-18.5% YoY
|
-91.32M
-91.69M – -90.94M
-67.3% YoY
|
-295.50M
-484.61M – -120.30M
-223.6% YoY
|
-652.18M
-1.07B – -265.51M
-120.7% YoY
|
| EBIT |
-132.76M
est: -8.9K (-1,485,908.5%)
|
-237.51M
est: -666.02M (+64.3%)
|
-338.48M
est: -339.84M (+0.4%)
|
-176.49M
est: -262.78M (+32.8%)
|
-415.57M
est: -38.32M (-984.4%)
|
-36.26M
est: -26.83M (-35.2%)
|
-47.63M
-66.38M – -16.96M
-77.6% YoY
|
-56.46M
-77.96M – -17.20M
-18.5% YoY
|
-94.45M
-94.84M – -94.06M
-67.3% YoY
|
-305.63M
-501.22M – -124.43M
-223.6% YoY
|
-674.53M
-1.11B – -274.61M
-120.7% YoY
|
| Net Income |
-194.59M
est: -240.12M (+19.0%)
|
-370.64M
est: -631.79M (+41.3%)
|
-289.09M
est: -298.25M (+3.1%)
|
-132.53M
est: -143.01M (+7.3%)
|
-376.74M
est: -458.81M (+17.9%)
|
-79.99M
est: -413.13M (+80.6%)
|
-479.24M
-485.84M – -389.92M
-16.0% YoY
|
-523.85M
-581.22M – -49.72M
-9.3% YoY
|
-523.59M
-752.62M – -278.86M
+0.0% YoY
|
-296.82M
-543.76M – -68.04M
+43.3% YoY
|
-30.00M
-54.96M – -6.88M
+89.9% YoY
|
| SGA |
29.61M
est: 2.48M (+1,095.5%)
|
57.22M
est: 2.87B (-98.0%)
|
87.81M
est: 13.42B (-99.3%)
|
116.81M
est: 382.51M (-69.5%)
|
111.53M
est: 55.78M (+99.9%)
|
113.82M
est: 39.05M (+191.5%)
|
69.34M
24.69M – 96.62M
+77.6% YoY
|
82.19M
25.04M – 113.47M
+18.5% YoY
|
137.48M
136.91M – 138.04M
+67.3% YoY
|
444.88M
181.11M – 729.58M
+223.6% YoY
|
981.85M
399.72M – 1.61B
+120.7% YoY
|
| EPS |
-5.49
est: -2.92 (-88.2%)
|
-5.77
est: -5.70 (-1.2%)
|
-4.13
est: -4.73 (+12.7%)
|
-1.72
est: -1.77 (+2.6%)
|
-4.58
est: -4.68 (+2.2%)
|
-0.81
est: -4.22 (+80.8%)
|
-4.43
-4.91 – -3.94
-4.9% YoY
|
-4.40
-5.88 – -0.50
+0.5% YoY
|
-4.52
-7.61 – -2.82
-2.7% YoY
|
-3.00
-5.50 – -0.69
+33.7% YoY
|
-0.30
-0.56 – -0.07
+89.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-260.19M
OE per share TTM
-2.55
Owner's Yield
-8.01%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
180.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
50
Total invested
123.28M
Insider transactions (90d)
1
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 4.62M | 5.66% | — | 4.43M | — | 4.62M | HC | BOSTON, MASSACHUSETTS | 2024-01-24 | ↗ |
| 2 | Andrew J. M. Spokes | 4.11M | 5.20% | — | 4.11M | — | — | IN | United Kingdom | 2023-09-22 | ↗ |
| 3 | Daniel S. Short | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 4 | David T. Kim | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 5 | Edric C. Saito | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 6 | Hannah E. Dunn | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 7 | John R. Warren | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 8 | Joshua J. Dapice | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 9 | Mark C. Wehrly | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 10 | Michael G. Linn | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 11 | Nicolas Giauque | 4.11M | 5.20% | — | 4.11M | — | — | IN | France | 2023-09-22 | ↗ |
| 12 | Philip D. Dreyfuss | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 13 | Rajiv A. Patel | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 14 | Richard B. Fried | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 15 | Thomas G. Roberts, Jr. | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 16 | Varun N. Gehani | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 17 | William Seybold | 4.11M | 5.20% | — | 4.11M | — | — | IN | United States | 2023-09-22 | ↗ |
| 18 | Farallon Partners, L.L.C. | 3.95M | 5.00% | — | 3.95M | — | — | OO | Delaware | 2023-09-22 | ↗ |
| 19 | 5.0%(1)(2) | 3.64M | 5.00% | — | 3.64M | — | 3.64M | HC | Republic of Singapore | 2023-03-17 | ↗ |
| 20 | Michael B. Fisch | 3.55M | 5.10% | — | 3.55M | — | — | IN | United States | 2022-07-14 | ↗ |
| 21 | Farallon Healthcare Partners (GP), L.L.C. | 2.08M | 2.60% | — | 2.08M | — | — | OO | Delaware | 2023-09-22 | ↗ |
| 22 | Farallon Healthcare Partners Master, L.P. | 2.08M | 2.60% | — | 2.08M | — | — | PN | Cayman Islands | 2023-09-22 | ↗ |
| 23 | Farallon Capital Offshore Investors II, L.P. | 824.6K | 1.00% | — | 824.6K | — | — | PN | Cayman Islands | 2023-09-22 | ↗ |
| 24 | Farallon Capital Institutional Partners, L.P. | 462.9K | 0.60% | — | 462.9K | — | — | PN | California | 2023-09-22 | ↗ |
| 25 | Farallon Capital Partners, L.P. | 306.5K | 0.40% | — | 306.5K | — | — | PN | California | 2023-09-22 | ↗ |
| 26 | Farallon Capital F5 Master I, L.P. | 163.8K | 0.20% | — | 163.8K | — | — | PN | Cayman Islands | 2023-09-22 | ↗ |
| 27 | Farallon F5 (GP), L.L.C. | 163.8K | 0.20% | — | 163.8K | — | — | OO | Delaware | 2023-09-22 | ↗ |
| 28 | Farallon Capital Institutional Partners II, L.P. | 111.2K | 0.10% | — | 111.2K | — | — | PN | California | 2023-09-22 | ↗ |
| 29 | Farallon Institutional (GP) V, L.L.C. | 74.8K | 0.10% | — | 74.8K | — | — | OO | Delaware | 2023-09-22 | ↗ |
| 30 | Four Crossings Institutional Partners V, L.P. | 74.8K | 0.10% | — | 74.8K | — | — | PN | Delaware | 2023-09-22 | ↗ |
| 31 | Farallon Capital Institutional Partners III, L.P. | 55.0K | 0.10% | — | 55.0K | — | — | PN | Delaware | 2023-09-22 | ↗ |
| 32 | Farallon Capital (AM) Investors, L.P. | 38.7K | 0.00% | — | 38.7K | — | — | PN | Delaware | 2023-09-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
50
-206 vs prev Q
New positions
12
Closed positions
207
Increased
30
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 476.3K +476.3K (+100.0%) | 13.20B +13.2B (+100.0%) | 0.46% +0.464 pp | 3.90% +3.897 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 2 | ARK INVESTMENT MANAGEMENT LLC | 12.47M +1.4M (+12.9%) | 345.59M +77.7M (+29.0%) | 12.15% +1.332 pp | 2.29% +0.699 pp | USD52.01 -46.7% | 21 qtrs — |
| 3 | FMR LLC | 11.91M +216.3K (+1.8%) | 330.12M +46.3M (+16.3%) | 11.61% +0.147 pp | 0.02% +0.002 pp | USD21.75 +27.4% | 24 qtrs — |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 10.06M +— (+0.0%) | 278.95M +34.7M (+14.2%) | 9.81% -0.055 pp | 1.32% +0.317 pp | USD40.32 -31.3% | 20 qtrs — |
| 5 | VANGUARD GROUP INC | 9.19M -57.3K (-0.6%) | 254.84M +30.3M (+13.5%) | 8.96% -0.107 pp | 0.00% +0.000 pp | USD42.33 -34.5% | 24 qtrs — |
| 6 | BLACKROCK, INC. | 8.45M +302.0K (+3.7%) | 234.24M +36.5M (+18.4%) | 8.24% +0.250 pp | 0.00% +0.001 pp | USD24.36 +13.8% | 6 qtrs — |
| 7 | STATE STREET CORP | 5.23M +1.2M (+30.4%) | 144.93M +47.6M (+49.0%) | 5.10% +1.167 pp | 0.00% +0.002 pp | USD34.97 -20.7% | 24 qtrs — |
| 8 | ARCH VENTURE MANAGEMENT, LLC | 4.54M +— (+0.0%) | 125.85M +15.7M (+14.2%) | 4.43% -0.025 pp | 19.31% -3.068 pp | USD23.05 +20.3% | 7 qtrs — |
| 9 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 4.41M -421.4K (-8.7%) | 122.23M +5.0M (+4.3%) | 4.30% -0.438 pp | 0.07% +0.004 pp | USD29.11 -4.8% | 21 qtrs — |
| 10 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 4.41M -421.4K (-8.7%) | 122.18M +4.9M (+4.2%) | 4.30% -0.438 pp | 1.41% +0.276 pp | USD29.09 -4.7% | 21 qtrs — |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.73M +467.1K (+20.6%) | 75.68M +20.8M (+37.8%) | 2.66% +0.443 pp | 0.01% +0.002 pp | USD26.34 +5.2% | 24 qtrs — |
| 12 | KYNAM CAPITAL MANAGEMENT, LP | 2.44M -77.4K (-3.1%) | 67.64M +6.5M (+10.7%) | 2.38% -0.089 pp | 4.32% -0.228 pp | USD23.10 +20.0% | 6 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2.35M -39.0K (-1.6%) | 65.21M +7.2M (+12.4%) | 2.29% -0.051 pp | 0.00% +0.000 pp | USD38.32 -27.7% | 24 qtrs — |
| 14 | DIMENSIONAL FUND ADVISORS LP | 1.95M +227.6K (+13.2%) | 54.00M +12.2M (+29.3%) | 1.90% +0.212 pp | 0.01% +0.002 pp | USD26.06 +6.4% | 20 qtrs — |
| 15 | UBS ASSET MANAGEMENT AMERICAS INC | 1.71M +47.0K (+2.8%) | 47.47M +7.0M (+17.4%) | 1.67% +0.037 pp | 0.01% +0.001 pp | USD27.10 +2.3% | 21 qtrs — |
| 16 | CASDIN CAPITAL, LLC | 1.60M +— (+0.0%) | 44.35M +5.5M (+14.2%) | 1.56% -0.009 pp | 2.75% -0.483 pp | USD37.46 -26.0% | 21 qtrs — |
| 17 | REDMILE GROUP, LLC | 1.29M -101.7K (-7.3%) | 35.64M +2.0M (+5.8%) | 1.25% -0.107 pp | 2.62% -0.652 pp | USD26.96 +2.8% | 24 qtrs — |
| 18 | TWO SIGMA INVESTMENTS, LP | 1.12M +741.3K (+195.6%) | 31.06M +21.9M (+237.6%) | 1.09% +0.721 pp | 0.04% +0.030 pp | USD25.35 +9.3% | 8 qtrs — |
| 19 | WOODLINE PARTNERS LP | 993.1K +446.5K (+81.7%) | 27.53M +14.3M (+107.5%) | 0.97% +0.432 pp | 0.11% +0.044 pp | USD24.29 +14.1% | 5 qtrs — |
| 20 | UBS GROUP AG | 973.8K -163.8K (-14.4%) | 26.99M -615.4K (-2.2%) | 0.95% -0.166 pp | 0.00% +0.000 pp | USD25.36 +9.3% | 24 qtrs — |
| 21 | MARSHALL WACE, LLP | 945.8K +945.8K (+100.0%) | 26.22M +26.2M (+100.0%) | 0.92% +0.922 pp | 0.02% +0.024 pp | USD27.72 +0.0% | 5 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 834.8K -6.4K (-0.8%) | 23.14M +2.7M (+13.3%) | 0.81% -0.011 pp | 0.00% +0.000 pp | USD41.45 -33.1% | 24 qtrs — |
| 23 | NORTHERN TRUST CORP | 808.9K -45.4K (-5.3%) | 22.42M +1.7M (+8.1%) | 0.79% -0.049 pp | 0.00% +0.000 pp | USD36.12 -23.3% | 24 qtrs — |
| 24 | MORGAN STANLEY | 729.4K +84.6K (+13.1%) | 20.22M +4.6M (+29.2%) | 0.71% +0.079 pp | 0.00% +0.000 pp | USD24.89 +11.4% | 24 qtrs — |
| 25 | JPMORGAN CHASE & CO | 619.2K +77.9K (+14.4%) | 17.17M +4.0M (+30.7%) | 0.60% +0.073 pp | 0.00% +0.000 pp | USD44.67 -37.9% | 24 qtrs — |
| 26 | RTW INVESTMENTS, LP | 570.4K +570.4K (+100.0%) | 15.81M +15.8M (+100.0%) | 0.56% +0.556 pp | 0.16% +0.158 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 27 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 550.0K +150.0K (+37.5%) | 15.25M +5.5M (+57.0%) | 0.54% +0.144 pp | 0.76% +0.100 pp | USD19.93 +39.1% | 3 qtrs — |
| 28 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 533.6K +150.0K (+39.1%) | 14.79M +5.5M (+58.9%) | 0.52% +0.144 pp | 1.02% +0.390 pp | USD23.18 +19.6% | 7 qtrs — |
| 29 | CAPTION MANAGEMENT, LLC | 532.5K +440.0K (+475.7%) | 14.76M +12.5M (+557.5%) | 0.52% +0.429 pp | 0.10% +0.084 pp | USD26.81 +3.4% | 8 qtrs — |
| 30 | TWO SIGMA ADVISERS, LP | 527.8K +194.8K (+58.5%) | 14.63M +6.5M (+81.0%) | 0.51% +0.188 pp | 0.03% +0.012 pp | USD21.47 +29.1% | 8 qtrs — |
| 31 | GOLDMAN SACHS GROUP INC | 522.6K -796.0K (-60.4%) | 14.49M -17.5M (-54.7%) | 0.51% -0.783 pp | 0.00% -0.002 pp | USD31.53 -12.1% | 24 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 500.2K +200.4K (+66.8%) | 13.87M +6.6M (+90.6%) | 0.49% +0.194 pp | 0.00% +0.001 pp | USD25.30 +9.6% | 21 qtrs — |
| 33 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 492.4K -767.6K (-60.9%) | 13.65M -16.9M (-55.4%) | 0.48% -0.755 pp | 0.05% -0.055 pp | USD20.09 +38.0% | 21 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 468.9K +444.9K (+1,856.2%) | 13.00M +12.4M (+2,134.3%) | 0.46% +0.434 pp | 0.01% +0.006 pp | USD27.20 +1.9% | 5 qtrs — |
| 35 | BANK OF AMERICA CORP /DE/ | 427.3K -351.7K (-45.1%) | 11.85M -7.1M (-37.3%) | 0.42% -0.347 pp | 0.00% 0.000 pp | USD20.66 +34.2% | 24 qtrs — |
| 36 | BAILLIE GIFFORD & CO | 416.2K +118.4K (+39.8%) | 11.54M +4.3M (+59.6%) | 0.41% +0.114 pp | 0.01% +0.004 pp | USD34.13 -18.8% | 21 qtrs — |
| 37 | QUBE RESEARCH & TECHNOLOGIES LTD | 399.7K +329.2K (+467.4%) | 11.08M +9.4M (+548.1%) | 0.39% +0.321 pp | 0.01% +0.010 pp | USD25.83 +7.3% | 3 qtrs — |
| 38 | BANK OF NEW YORK MELLON CORP | 357.7K -51.8K (-12.6%) | 9.91M -22.5K (-0.2%) | 0.35% -0.053 pp | 0.00% 0.000 pp | USD38.10 -27.2% | 24 qtrs — |
| 39 | PICTET ASSET MANAGEMENT HOLDING SA | 325.7K -11.9K (-3.5%) | 9.06M +989.0K (+12.2%) | 0.32% -0.013 pp | 0.01% +0.001 pp | USD18.81 +47.4% | 10 qtrs — |
| 40 | BARCLAYS PLC | 326.2K +143.0K (+78.0%) | 9.04M +4.6M (+101.4%) | 0.32% +0.138 pp | 0.00% +0.001 pp | USD23.15 +19.7% | 16 qtrs — |
| 41 | ALPHABET INC. | 321.6K +— (+0.0%) | 8.91M +1.1M (+14.2%) | 0.31% -0.002 pp | 0.35% +0.022 pp | USD18.00 +54.0% | 24 qtrs — |
| 42 | MILLENNIUM MANAGEMENT LLC | 301.7K +271.9K (+913.9%) | 8.36M +7.6M (+1,058.1%) | 0.29% +0.265 pp | 0.00% +0.003 pp | USD28.12 -1.4% | 24 qtrs — |
| 43 | PEREGRINE INVESTMENT MANAGEMENT INC | 257.3K -10.7K (-4.0%) | 7.13M +629.1K (+9.7%) | 0.25% -0.012 pp | 4.43% +1.234 pp | USD22.34 +24.1% | 5 qtrs — |
| 44 | CITADEL ADVISORS LLC | 255.7K +255.7K (+100.0%) | 7.09M +7.1M (+100.0%) | 0.25% +0.249 pp | 0.00% +0.001 pp | USD27.72 +0.0% | 24 qtrs — |
| 45 | NUVEEN, LLC | 233.1K -4.3K (-1.8%) | 6.46M +700.3K (+12.2%) | 0.23% -0.006 pp | 0.00% +0.000 pp | USD19.30 +43.6% | 4 qtrs — |
| 46 | INVESCO LTD. | 213.2K +36.3K (+20.5%) | 5.91M +1.6M (+37.7%) | 0.21% +0.034 pp | 0.00% +0.000 pp | USD32.27 -14.1% | 21 qtrs — |
| 47 | VESTMARK ADVISORY SOLUTIONS, INC. | 196.0K +29.7K (+17.9%) | 5.43M +1.4M (+34.6%) | 0.19% +0.028 pp | 0.07% -0.004 pp | USD22.39 +23.8% | 9 qtrs — |
| 48 | TD ASSET MANAGEMENT INC | 191.2K +46.1K (+31.7%) | 5.30M +1.8M (+50.5%) | 0.19% +0.044 pp | 0.00% +0.001 pp | USD29.48 -6.0% | 8 qtrs — |
| 49 | SWISS NATIONAL BANK | 179.5K +4.1K (+2.3%) | 4.98M +718.8K (+16.9%) | 0.18% +0.003 pp | 0.00% +0.001 pp | USD47.28 -41.4% | 23 qtrs — |
| 50 | RAFFERTY ASSET MANAGEMENT, LLC | 176.9K +39.7K (+29.0%) | 4.90M +1.6M (+47.3%) | 0.17% +0.038 pp | 0.02% +0.006 pp | USD35.58 -22.1% | 21 qtrs — |
| 51 | LIONTRUST INVESTMENT PARTNERS LLP | 170.4K +170.4K (+100.0%) | 4.72M +4.7M (+100.0%) | 0.17% +0.166 pp | 0.07% +0.070 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 52 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 163.3K +163.3K (+100.0%) | 4.53M +4.5M (+100.0%) | 0.16% +0.159 pp | 0.04% +0.036 pp | USD27.72 +0.0% | 5 qtrs — |
| 53 | WELLS FARGO & COMPANY/MN | 159.2K +41.9K (+35.7%) | 4.41M +1.6M (+55.0%) | 0.16% +0.040 pp | 0.00% +0.000 pp | USD26.90 +3.0% | 24 qtrs — |
| 54 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 157.0K +11.6K (+8.0%) | 4.36M +835.7K (+23.7%) | 0.15% +0.011 pp | 0.00% +0.001 pp | USD29.97 -7.5% | 22 qtrs — |
| 55 | RENAISSANCE TECHNOLOGIES LLC | 156.5K +156.5K (+100.0%) | 4.34M +4.3M (+100.0%) | 0.15% +0.153 pp | 0.01% +0.007 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 56 | HRT FINANCIAL LP | 151.2K -11.5K (-7.1%) | 4.19M +242.0K (+6.1%) | 0.15% -0.012 pp | 0.01% -0.001 pp | USD24.27 +14.2% | 2 qtrs — |
| 57 | AMERICAN CENTURY COMPANIES INC | 148.3K +98.1K (+195.5%) | 4.11M +2.9M (+237.5%) | 0.14% +0.095 pp | 0.00% +0.001 pp | USD26.67 +3.9% | 10 qtrs — |
| 58 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 138.1K +— (+0.0%) | 3.83M +476.6K (+14.2%) | 0.13% -0.001 pp | 0.06% +0.006 pp | USD17.78 +55.9% | 3 qtrs — |
| 59 | SUMMITTX CAPITAL, L.P. | 137.9K +121.7K (+751.0%) | 3.82M +3.4M (+872.0%) | 0.13% +0.119 pp | 0.12% +0.099 pp | USD27.31 +1.5% | 4 qtrs — |
| 60 | RHUMBLINE ADVISERS | 131.2K -12.6K (-8.8%) | 3.64M +146.1K (+4.2%) | 0.13% -0.013 pp | 0.00% +0.000 pp | USD34.93 -20.6% | 24 qtrs — |
| 61 | SCHONFELD STRATEGIC ADVISORS LLC | 128.4K -167.7K (-56.6%) | 3.56M -3.6M (-50.5%) | 0.13% -0.165 pp | 0.02% -0.025 pp | USD18.66 +48.6% | 19 qtrs — |
| 62 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 112.8K +4.1K (+3.8%) | 3.13M +491.9K (+18.7%) | 0.11% +0.003 pp | 0.00% +0.001 pp | USD23.19 +19.5% | 7 qtrs — |
| 63 | BELLEVUE GROUP AG | 111.5K -2.8M (-96.1%) | 3.09M -67.0M (-95.6%) | 0.11% -2.724 pp | 0.06% -1.398 pp | USD35.52 -22.0% | 21 qtrs — |
| 64 | SG AMERICAS SECURITIES, LLC | 103.5K +60.2K (+139.4%) | 2.87M +1.8M (+173.4%) | 0.10% +0.059 pp | 0.00% +0.000 pp | USD26.16 +6.0% | 20 qtrs — |
| 65 | ALLIANCEBERNSTEIN L.P. | 100.7K +— (+0.0%) | 2.79M +347.5K (+14.2%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD27.85 -0.5% | 24 qtrs — |
| 66 | D.A. DAVIDSON & CO. | 98.9K +4.3K (+4.5%) | 2.74M +444.4K (+19.3%) | 0.10% +0.004 pp | 0.02% +0.002 pp | USD30.13 -8.0% | 18 qtrs — |
| 67 | LEGAL & GENERAL GROUP PLC | 92.1K -7.5K (-7.5%) | 2.55M +135.9K (+5.6%) | 0.09% -0.008 pp | 0.00% +0.000 pp | USD44.42 -37.6% | 24 qtrs — |
| 68 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 87.3K +4.2K (+5.1%) | 2.42M +403.3K (+20.0%) | 0.09% +0.004 pp | 0.00% +0.000 pp | USD34.41 -19.4% | 24 qtrs — |
| 69 | DEUTSCHE BANK AG\ | 77.6K +4.6K (+6.4%) | 2.15M +380.4K (+21.5%) | 0.08% +0.004 pp | 0.00% +0.000 pp | USD24.64 +12.5% | 24 qtrs — |
| 70 | CONCURRENT INVESTMENT ADVISORS, LLC | 76.8K +76.8K (+100.0%) | 2.13M +2.1M (+100.0%) | 0.07% +0.075 pp | 0.02% +0.024 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 71 | PRIVIUM FUND MANAGEMENT B.V. | 71.5K +10.5K (+17.2%) | 1.98M +501.5K (+33.9%) | 0.07% +0.010 pp | 0.36% +0.099 pp | USD24.78 +11.9% | 2 qtrs — |
| 72 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 70.0K -316.0 (-0.4%) | 1.95M +239.7K (+14.1%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD21.74 +27.5% | 4 qtrs — |
| 73 | JANE STREET GROUP, LLC | 66.6K -14.9K (-18.3%) | 1.85M -131.9K (-6.7%) | 0.06% -0.015 pp | 0.00% +0.000 pp | USD19.07 +45.4% | 6 qtrs — |
| 74 | DEKABANK DEUTSCHE GIROZENTRALE | 50.0K +— (+0.0%) | 1.85M +19.0K (+1.0%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD50.90 -45.5% | 21 qtrs — |
| 75 | PROFUND ADVISORS LLC | 65.6K +35.6K (+118.4%) | 1.82M +1.1M (+149.4%) | 0.06% +0.035 pp | 0.06% +0.032 pp | USD29.29 -5.4% | 18 qtrs — |
| 76 | FIRST TRUST ADVISORS LP | 64.1K +64.1K (+100.0%) | 1.78M +1.8M (+100.0%) | 0.06% +0.063 pp | 0.00% +0.001 pp | USD27.72 +0.0% | 1 qtrs NEW |
| 77 | BOOTHBAY FUND MANAGEMENT, LLC | 60.8K -7.8K (-11.3%) | 1.68M +21.4K (+1.3%) | 0.06% -0.008 pp | 0.03% +0.001 pp | USD24.27 +14.2% | 2 qtrs — |
| 78 | CLARIUS GROUP, LLC | 60.6K +— (+0.0%) | 1.68M +209.1K (+14.2%) | 0.06% 0.000 pp | 0.10% +0.009 pp | USD37.84 -26.7% | 19 qtrs — |
| 79 | STATE OF WISCONSIN INVESTMENT BOARD | 58.5K +11.3K (+23.8%) | 1.62M +475.0K (+41.4%) | 0.06% +0.011 pp | 0.00% +0.001 pp | USD55.17 -49.8% | 24 qtrs — |
| 80 | VOYA INVESTMENT MANAGEMENT LLC | 56.1K +38.9K (+226.8%) | 1.55M +1.1M (+273.2%) | 0.05% +0.038 pp | 0.00% +0.001 pp | USD33.21 -16.5% | 22 qtrs — |
| 81 | LPL FINANCIAL LLC | 55.6K +11.9K (+27.1%) | 1.54M +480.0K (+45.2%) | 0.05% +0.011 pp | 0.00% +0.000 pp | USD36.03 -23.1% | 21 qtrs — |
| 82 | METLIFE INVESTMENT MANAGEMENT, LLC | 54.5K -2.1K (-3.6%) | 1.51M +138.3K (+10.1%) | 0.05% -0.002 pp | 0.01% +0.001 pp | USD33.78 -17.9% | 24 qtrs — |
| 83 | GENERALI INVESTMENTS TOWARZYSTWO FUNDUSZY INWESTYCYJNYCH | 45.0K -6.0K (-11.8%) | 1.25M +9.6K (+0.8%) | 0.04% -0.006 pp | 0.61% -0.049 pp | USD22.13 +25.3% | 7 qtrs — |
| 84 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 43.8K +6.4K (+17.0%) | 1.21M +305.3K (+33.6%) | 0.04% +0.006 pp | 0.00% +0.001 pp | USD36.74 -24.6% | 21 qtrs — |
| 85 | RAIFFEISEN BANK INTERNATIONAL AG | 43.0K +— (+0.0%) | 1.20M +168.1K (+16.4%) | 0.04% 0.000 pp | 0.02% +0.002 pp | USD24.70 +12.2% | 5 qtrs — |
| 86 | WCG WEALTH ADVISORS LLC | 39.9K +15.8K (+65.2%) | 1.11M +520.1K (+88.7%) | 0.04% +0.015 pp | 0.03% -0.006 pp | USD25.63 +8.2% | 2 qtrs — |
| 87 | VIRGINIA RETIREMENT SYSTEMS ET AL | 39.5K -2.3K (-5.5%) | 1.10M +80.6K (+7.9%) | 0.04% -0.003 pp | 0.01% 0.000 pp | USD19.32 +43.5% | 4 qtrs — |
| 88 | JANUS HENDERSON GROUP PLC | 39.5K +— (+0.0%) | 1.09M +135.7K (+14.1%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD19.80 +40.0% | 16 qtrs — |
| 89 | INTECH INVESTMENT MANAGEMENT LLC | 38.1K +10.2K (+36.8%) | 1.05M +379.5K (+56.2%) | 0.04% +0.010 pp | 0.01% +0.003 pp | USD24.02 +15.4% | 6 qtrs — |
| 90 | WELLINGTON MANAGEMENT GROUP LLP | 36.9K -1.1K (-2.9%) | 1.02M +101.0K (+10.9%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD26.66 +4.0% | 9 qtrs — |
| 91 | BENJAMIN EDWARDS INC | 35.8K +3.1K (+9.4%) | 992.3K +198.1K (+24.9%) | 0.03% +0.003 pp | 0.01% +0.002 pp | USD23.47 +18.1% | 13 qtrs — |
| 92 | ALGERT GLOBAL LLC | 34.3K +34.3K (+100.0%) | 951.0K +951.0K (+100.0%) | 0.03% +0.033 pp | 0.01% +0.015 pp | USD27.72 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
5
Shares acquired
—
Shares disposed
57.8K
Cash buys
—
Cash sales
5.00
Net activity
-57,786
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2033-06-06 | Walsh Kathleen E | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2026-04-01 | Simon Amy | Officer | S-Sale | D | Common Stock | 6,700 | 24.58 | 164.7K | 102,735 | D | ↗ |
| 2026-04-01 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 30,078 | 24.58 | 739.3K | 1,047,205 | D | ↗ |
| 2026-04-01 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 11,810 | 24.58 | 290.3K | 218,406 | D | ↗ |
| 2026-04-01 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 3,242 | 24.58 | 79.7K | 51,171 | D | ↗ |
| 2026-04-01 | Bellon Christine | Officer | S-Sale | D | Common Stock | 5,956 | 24.58 | 146.4K | 109,711 | D | ↗ |
| 2026-03-31 | Simon Amy | Officer | A-Award | A | Common Stock | 31,750 | 0.00 | — | 109,114 | D | ↗ |
| 2026-03-31 | Evans John M. | Director / Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 1,076,667 | D | ↗ |
| 2026-03-31 | Emany Sravan Kumar | Officer | A-Award | A | Common Stock | 31,750 | 0.00 | — | 105,456 | D | ↗ |
| 2026-03-31 | Ciaramella Giuseppe | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 230,216 | D | ↗ |
| 2026-03-31 | Cavanagh Bethany J | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 54,813 | D | ↗ |
| 2026-03-31 | Bellon Christine | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 115,667 | D | ↗ |
| 2026-03-30 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 25,000 | 22.37 | 559.2K | 986,667 | D | ↗ |
| 2026-02-24 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 35,000 | 32.00 | 1.12M | 190,216 | D | ↗ |
| 2026-01-31 | Simon Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 88,500 | 27.62 | 2.44M | 88,500 | D | ↗ |
| 2026-01-31 | Evans John M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 27.62 | 4.97M | 180,000 | D | ↗ |
| 2026-01-31 | Emany Sravan Kumar | Officer | A-Award | A | Stock Option (Right to Buy) | 63,500 | 27.62 | 1.75M | 63,500 | D | ↗ |
| 2026-01-31 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 27.62 | 2.21M | 80,000 | D | ↗ |
| 2026-01-31 | Cavanagh Bethany J | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 27.62 | 1.10M | 40,000 | D | ↗ |
| 2026-01-31 | Bellon Christine | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 27.62 | 1.10M | 40,000 | D | ↗ |
| 2026-01-30 | Evans John M. | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.67 | 16.8K | 1,011,667 | D | ↗ |
| 2026-01-29 | Evans John M. | Director / Officer | M-Exempt | A | Common Stock | 19,336 | 0.67 | 13.0K | 1,006,003 | D | ↗ |
| 2026-01-22 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 6,198 | 35.00 | 216.9K | 34,813 | D | ↗ |
| 2026-01-22 | Bellon Christine | Officer | S-Sale | D | Common Stock | 1,371 | 34.00 | 46.6K | 95,667 | D | ↗ |
| 2026-01-20 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 3,034 | 30.12 | 91.4K | 41,011 | D | ↗ |
| 2026-01-15 | Bellon Christine | Officer | S-Sale | D | Common Stock | 2,111 | 33.62 | 71.0K | 113,556 | D | ↗ |
| 2025-12-31 | Simon Amy | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 77,364 | D | ↗ |
| 2025-12-31 | Emany Sravan Kumar | Officer | S-Sale | D | Common Stock | 6,294 | 27.10 | 170.6K | 73,706 | D | ↗ |
| 2025-12-31 | Bellon Christine | Officer | S-Sale | D | Common Stock | 1,254 | 27.10 | 34.0K | 115,667 | D | ↗ |
| 2025-10-27 | FMR LLC | 10% Owner | S-Sale | D | Common Stock | 459 | 26.68 | 12.2K | 14 | I | ↗ |
| 2025-10-06 | FMR LLC | 10% Owner | G-Gift | D | Common Stock | 1,232,434 | 0.00 | — | 841,231 | I | ↗ |
| 2025-10-02 | Evans John M. | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.67 | 16.8K | 1,011,667 | D | ↗ |
| 2025-10-01 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 25,000 | 24.51 | 612.7K | 986,667 | D | ↗ |
| 2025-10-01 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 467 | 24.53 | 11.5K | 44,045 | D | ↗ |
| 2025-10-01 | Bellon Christine | Officer | S-Sale | D | Common Stock | 373 | 24.53 | 9.1K | 116,921 | D | ↗ |
| 2025-07-30 | FMR LLC | 10% Owner | S-Sale | D | Common Stock | 48,374 | 20.50 | 991.7K | 2,073,665 | I | ↗ |
| 2025-07-03 | Simon Amy | Officer | S-Sale | D | Common Stock | 876 | 20.12 | 17.6K | 64,864 | D | ↗ |
| 2025-07-01 | Simon Amy | Officer | S-Sale | D | Common Stock | 374 | 16.94 | 6.3K | 65,740 | D | ↗ |
| 2025-06-04 | Walsh Kathleen E | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | Shaw Christi | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | Ho Carole | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | Guindo Chirfi | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | Fishman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-06-04 | COOPER GRAHAM K | Director | A-Award | A | Stock Option (Right to Buy) | 33,662 | 17.15 | 577.3K | 33,662 | D | ↗ |
| 2025-04-02 | Simon Amy | Officer | S-Sale | D | Common Stock | 20,997 | 17.73 | 372.3K | 65,742 | D | ↗ |
| 2025-04-01 | Simon Amy | Officer | S-Sale | D | Common Stock | 9,566 | 18.35 | 175.5K | 86,739 | D | ↗ |
| 2025-04-01 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 30,663 | 18.35 | 562.7K | 986,249 | D | ↗ |
| 2025-04-01 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 7,434 | 18.35 | 136.4K | 190,216 | D | ↗ |
| 2025-04-01 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 3,015 | 18.35 | 55.3K | 44,512 | D | ↗ |
| 2025-04-01 | Bellon Christine | Officer | S-Sale | D | Common Stock | 5,674 | 18.35 | 104.1K | 117,294 | D | ↗ |
| 2025-03-31 | Simon Amy | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 96,305 | D | ↗ |
| 2025-03-31 | FMR LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 473 | I | ↗ |
| 2025-03-31 | Evans John M. | Director / Officer | A-Award | A | Common Stock | 77,500 | 0.00 | — | 1,016,159 | D | ↗ |
| 2025-03-31 | Ciaramella Giuseppe | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 197,650 | D | ↗ |
| 2025-03-31 | Cavanagh Bethany J | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 47,527 | D | ↗ |
| 2025-03-31 | Bellon Christine | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 122,968 | D | ↗ |
| 2025-02-18 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 6,287 | 35.00 | 220.0K | 37,527 | D | ↗ |
| 2025-02-14 | Bellon Christine | Officer | M-Exempt | A | Common Stock | 508 | 7.22 | 3.7K | 112,968 | D | ↗ |
| 2025-01-31 | Simon Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 25.92 | 1.43M | 55,000 | D | ↗ |
| 2025-01-31 | Evans John M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 25.92 | 4.02M | 155,000 | D | ↗ |
| 2025-01-31 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 25.92 | 1.81M | 70,000 | D | ↗ |
| 2025-01-31 | Cavanagh Bethany J | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 25.92 | 518.4K | 20,000 | D | ↗ |
| 2025-01-31 | Bellon Christine | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 25.92 | 1.04M | 40,000 | D | ↗ |
| 2025-01-30 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 29,800 | 26.75 | 797.0K | 908,859 | D | ↗ |
| 2025-01-02 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 1,117 | 24.68 | 27.6K | 43,814 | D | ↗ |
| 2025-01-02 | Bellon Christine | Officer | S-Sale | D | Common Stock | 1,241 | 24.68 | 30.6K | 102,968 | D | ↗ |
| 2024-12-31 | Emany Sravan Kumar | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 24.80 | 3.97M | 160,000 | D | ↗ |
| 2024-12-19 | Emany Sravan Kumar | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-17 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 53,500 | 0.67 | 35.8K | 6,505 | D | ↗ |
| 2024-12-02 | Guindo Chirfi | Director | A-Award | A | Stock Option (Right to Buy) | 39,086 | 28.30 | 1.11M | 39,086 | D | ↗ |
| 2024-11-06 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 51,110 | 26.36 | 1.35M | 109,150 | D | ↗ |
| 2024-10-14 | Ciaramella Giuseppe | Officer | M-Exempt | A | Common Stock | 1,457 | 7.22 | 10.5K | 211,370 | D | ↗ |
| 2024-10-01 | Cavanagh Bethany J | Officer | S-Sale | D | Common Stock | 289 | 23.48 | 6.8K | 44,931 | D | ↗ |
| 2024-10-01 | Bellon Christine | Officer | S-Sale | D | Common Stock | 385 | 23.48 | 9.0K | 104,209 | D | ↗ |
| 2024-09-30 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 60,000 | 24.60 | 1.48M | 938,659 | D | ↗ |
| 2024-09-30 | Cavanagh Bethany J | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 45,220 | D | ↗ |
| 2024-08-31 | Cavanagh Bethany J | Officer | A-Award | A | Stock Option (Right to Buy) | 5,000 | 26.68 | 133.4K | 5,000 | — | ↗ |
| 2024-08-09 | Cavanagh Bethany J | Officer | — | D | Common Stock | 0 | 0.00 | — | 42,720 | — | ↗ |
| 2024-07-02 | Simon Amy | Officer | S-Sale | D | Common Stock | 748 | 22.95 | 17.2K | 68,805 | — | ↗ |
| 2024-07-01 | Simon Amy | Officer | S-Sale | D | Common Stock | 502 | 23.76 | 11.9K | 69,553 | — | ↗ |
| 2024-06-27 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 60,000 | 24.50 | 1.47M | 998,343 | — | ↗ |
| 2024-06-05 | Walsh Kathleen E | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-06-05 | Shaw Christi | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-06-05 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-06-05 | Ho Carole | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-06-05 | Fishman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-06-05 | COOPER GRAHAM K | Director | A-Award | A | Stock Option (Right to Buy) | 23,114 | 24.49 | 566.1K | 23,114 | — | ↗ |
| 2024-04-26 | Burrell Terry-Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 30.87 | 771.8K | 25,000 | — | ↗ |
| 2024-04-03 | Evans John M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 53,965 | 4.22 | 227.7K | 53,965 | — | ↗ |
| 2024-04-03 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 12,979 | 4.22 | 54.8K | 12,979 | — | ↗ |
| 2024-04-02 | Simon Amy | Officer | S-Sale | D | Common Stock | 16,530 | 30.54 | 504.9K | 70,060 | — | ↗ |
| 2024-04-01 | Simon Amy | Officer | S-Sale | D | Common Stock | 7,157 | 32.13 | 230.0K | 86,590 | — | ↗ |
| 2024-04-01 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 18,102 | 32.13 | 581.6K | 1,058,343 | — | ↗ |
| 2024-04-01 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 4,534 | 32.12 | 145.6K | 169,616 | — | ↗ |
| 2024-04-01 | Burrell Terry-Ann | Officer | S-Sale | D | Common Stock | 5,446 | 32.12 | 174.9K | 70,137 | — | ↗ |
| 2024-04-01 | Bellon Christine | Officer | S-Sale | D | Common Stock | 3,401 | 32.12 | 109.2K | 104,594 | — | ↗ |
| 2024-03-31 | Simon Amy | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 93,747 | — | ↗ |
| 2024-03-31 | Evans John M. | Director / Officer | A-Award | A | Common Stock | 77,500 | 0.00 | — | 1,076,445 | — | ↗ |
| 2024-03-31 | Ciaramella Giuseppe | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 174,150 | — | ↗ |
| 2024-03-31 | Burrell Terry-Ann | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 75,583 | — | ↗ |
| 2024-03-31 | Bellon Christine | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 107,995 | — | ↗ |
| 2024-03-28 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 60,000 | 33.86 | 2.03M | 998,262 | — | ↗ |
| 2024-02-14 | FMR LLC | Other | S-Sale | D | Common Stock | 854,323 | 30.51 | 26.07M | 1,281,188 | — | ↗ |
| 2024-02-13 | FMR LLC | Other | S-Sale | D | Common Stock | 410 | 30.28 | 12.4K | 2,773,068 | — | ↗ |
| 2024-01-31 | Simon Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 24.40 | 1.34M | 55,000 | — | ↗ |
| 2024-01-31 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 60,000 | 25.33 | 1.52M | 1,058,262 | — | ↗ |
| 2024-01-31 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 24.40 | 1.71M | 70,000 | — | ↗ |
| 2024-01-31 | Burrell Terry-Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 24.40 | 1.34M | 55,000 | — | ↗ |
| 2024-01-31 | Bellon Christine | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 24.40 | 1.34M | 55,000 | — | ↗ |
| 2024-01-03 | Bellon Christine | Officer | S-Sale | D | Common Stock | 1,907 | 26.42 | 50.4K | 80,495 | — | ↗ |
| 2023-12-22 | FMR LLC | 10% Owner | J-Other | D | Common Stock | 29,549 | 0.00 | — | 2,773,478 | — | ↗ |
| 2023-12-13 | Shaw Christi | Director | A-Award | A | Stock Option (Right to Buy) | 39,046 | 28.28 | 1.10M | 39,046 | — | ↗ |
| 2023-11-20 | Bellon Christine | Officer | S-Sale | D | Common Stock | 5,000 | 31.00 | 155.0K | 82,402 | — | ↗ |
| 2023-10-30 | Simon Amy | Officer | S-Sale | D | Common Stock | 3,448 | 18.70 | 64.5K | 65,469 | — | ↗ |
| 2023-10-20 | Ciaramella Giuseppe | Officer | M-Exempt | A | Common Stock | 90,900 | 0.67 | 60.9K | 139,150 | — | ↗ |
| 2023-10-02 | Bellon Christine | Officer | S-Sale | D | Common Stock | 388 | 22.85 | 8.9K | 82,402 | — | ↗ |
| 2023-07-24 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,206 | 7.22 | 8.7K | 19,002 | — | ↗ |
| 2023-07-21 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 155,324 | 32.06 | 4.98M | 48,250 | — | ↗ |
| 2023-07-10 | Simon Amy | Officer | S-Sale | D | Common Stock | 391 | 30.48 | 11.9K | 68,917 | — | ↗ |
| 2023-06-06 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2023-06-06 | Ho Carole | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2023-06-06 | Fishman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2023-06-06 | COOPER GRAHAM K | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2023-06-06 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 16,532 | 34.33 | 567.5K | 16,532 | — | ↗ |
| 2023-04-04 | Simon Amy | Officer | S-Sale | D | Common Stock | 1,161 | 29.09 | 33.8K | 69,308 | — | ↗ |
| 2023-04-04 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 6,493 | 29.09 | 188.9K | 1,117,979 | — | ↗ |
| 2023-04-04 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 1,754 | 29.09 | 51.0K | 112,290 | — | ↗ |
| 2023-04-04 | Burrell Terry-Ann | Officer | S-Sale | D | Common Stock | 2,186 | 29.09 | 63.6K | 47,117 | — | ↗ |
| 2023-04-04 | Bellon Christine | Officer | S-Sale | D | Common Stock | 1,161 | 29.09 | 33.8K | 82,790 | — | ↗ |
| 2023-04-03 | Simon Amy | Officer | S-Sale | D | Common Stock | 4,445 | 30.31 | 134.7K | 80,962 | — | ↗ |
| 2023-04-03 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 5,161 | 30.31 | 156.4K | 1,124,472 | — | ↗ |
| 2023-04-03 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 1,918 | 30.31 | 58.1K | 114,044 | — | ↗ |
| 2023-04-03 | Burrell Terry-Ann | Officer | S-Sale | D | Common Stock | 2,454 | 30.31 | 74.4K | 49,303 | — | ↗ |
| 2023-04-03 | Bellon Christine | Officer | S-Sale | D | Common Stock | 931 | 30.31 | 28.2K | 83,951 | — | ↗ |
| 2023-03-31 | Simon Amy | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 85,129 | — | ↗ |
| 2023-03-31 | Evans John M. | Director / Officer | M-Exempt | A | Common Stock | 13,850 | 7.22 | 100.0K | 1,129,153 | — | ↗ |
| 2023-03-31 | Ciaramella Giuseppe | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 115,962 | — | ↗ |
| 2023-03-31 | Burrell Terry-Ann | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 51,277 | — | ↗ |
| 2023-03-31 | Bellon Christine | Officer | A-Award | A | Common Stock | 17,500 | 0.00 | — | 84,882 | — | ↗ |
| 2023-03-30 | Bellon Christine | Officer | M-Exempt | A | Common Stock | 2,669 | 7.22 | 19.3K | 67,382 | — | ↗ |
| 2023-03-16 | Simon Amy | Officer | — | D | Stock Option (Right to Buy) | 40,000 | 43.45 | 1.74M | 0 | — | ↗ |
| 2023-03-16 | Bellon Christine | Officer | — | D | Stock Option (Right to Buy) | 10,000 | 110.92 | 1.11M | 0 | — | ↗ |
| 2023-03-06 | Evans John M. | Director / Officer | L-Small | A | Common Stock | 225 | 0.00 | — | 1,059,053 | — | ↗ |
| 2023-01-31 | Evans John M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 112,500 | 43.45 | 4.89M | 112,500 | — | ↗ |
| 2023-01-31 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 43.45 | 1.74M | 40,000 | — | ↗ |
| 2023-01-31 | Burrell Terry-Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 43.45 | 869.0K | 20,000 | — | ↗ |
| 2023-01-27 | Burrell Terry-Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 36,152 | 0.00 | — | 185,565 | — | ↗ |
| 2023-01-26 | Burrell Terry-Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,102 | 0.00 | — | 221,717 | — | ↗ |
| 2023-01-24 | Burrell Terry-Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,810 | 0.00 | — | 222,819 | — | ↗ |
| 2023-01-23 | Burrell Terry-Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,426 | 0.00 | — | 237,629 | — | ↗ |
| 2023-01-18 | Burrell Terry-Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 39,886 | 0.00 | — | 243,055 | — | ↗ |
| 2023-01-03 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,326 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,500 | 0.00 | — | 191,202 | — | ↗ |
| 2022-12-12 | Ciaramella Giuseppe | Officer | M-Exempt | A | Common Stock | 18,211 | 0.67 | 12.2K | 133,825 | — | ↗ |
| 2022-10-31 | Evans John M. | Officer | S-Sale | D | Common Stock | 7,567 | 44.92 | 339.9K | 1,080,953 | — | ↗ |
| 2022-09-06 | FMR LLC | Director | J-Other | A | Common Stock | 551 | 0.00 | — | 551 | — | ↗ |
| 2022-09-01 | Walsh Kathleen E | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 0.00 | — | 10,391 | — | ↗ |
| 2022-09-01 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 0.00 | — | 10,391 | — | ↗ |
| 2022-09-01 | Ho Carole | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 55.58 | 577.5K | 10,391 | — | ↗ |
| 2022-09-01 | Fishman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 55.58 | 577.5K | 10,391 | — | ↗ |
| 2022-09-01 | COOPER GRAHAM K | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 0.00 | — | 10,391 | — | ↗ |
| 2022-09-01 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 10,391 | 55.58 | 577.5K | 10,391 | — | ↗ |
| 2022-08-05 | FMR LLC | 10% Owner | S-Sale | D | Common Stock | 20,159 | 60.50 | 1.22M | 0 | — | ↗ |
| 2022-08-04 | FMR LLC | 10% Owner | J-Other | D | Common Stock | 167,564 | 0.00 | — | 25,620 | — | ↗ |
| 2022-07-28 | Evans John M. | Officer | S-Sale | D | Common Stock | 10,599 | 65.92 | 698.7K | 125,448 | — | ↗ |
| 2022-04-28 | Evans John M. | Officer | S-Sale | D | Common Stock | 4,503 | 39.49 | 177.8K | 1,119,620 | — | ↗ |
| 2022-04-13 | FMR LLC | 10% Owner | S-Sale | D | Common Stock | 6,799 | 50.70 | 344.7K | 12,004 | — | ↗ |
| 2022-04-12 | FMR LLC | Director | S-Sale | D | Common Stock | 663 | 50.75 | 33.6K | 0 | — | ↗ |
| 2022-03-31 | Evans John M. | Officer | A-Award | A | Common Stock | 56,250 | 0.00 | — | 1,095,331 | — | ↗ |
| 2022-03-31 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 1,859 | 59.11 | 109.9K | 115,614 | — | ↗ |
| 2022-03-31 | Burrell Terry-Ann | Officer | S-Sale | D | Common Stock | 1,787 | 59.11 | 105.6K | 38,278 | — | ↗ |
| 2022-01-31 | Evans John M. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 1.03 | 103.0K | 284,345 | — | ↗ |
| 2022-01-31 | Ciaramella Giuseppe | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 69.21 | 2.08M | 30,000 | — | ↗ |
| 2022-01-31 | Burrell Terry-Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 69.21 | 2.08M | 30,000 | — | ↗ |
| 2022-01-20 | FMR LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,914,014 | — | ↗ |
| 2021-12-29 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 39,700 | 0.67 | 26.6K | 207,702 | — | ↗ |
| 2021-12-22 | Ciaramella Giuseppe | Officer | M-Exempt | A | Common Stock | 2,607 | 7.22 | 18.8K | 65,380 | — | ↗ |
| 2021-12-21 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,104 | 7.22 | 181.3K | 92,253 | — | ↗ |
| 2021-12-20 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,289 | 7.22 | 31.0K | 117,357 | — | ↗ |
| 2021-11-16 | Evans John M. | Director / Officer | G-Gift | D | Common Stock | 12,000 | 0.00 | — | 968,825 | — | ↗ |
| 2021-11-05 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 13,133 | 89.53 | 1.18M | 13,133 | — | ↗ |
| 2021-10-06 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 7,566 | 84.45 | 638.9K | 183,400 | — | ↗ |
| 2021-09-17 | Ciaramella Giuseppe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 18,012 | 0.67 | 12.1K | 247,402 | — | ↗ |
| 2021-08-25 | FMR LLC | Other | J-Other | D | Common Stock | 969,038 | 0.00 | — | 304 | — | ↗ |
| 2021-08-24 | FMR LLC | Director | J-Other | A | Common Stock | 1,569 | 0.00 | — | 2,293 | — | ↗ |
| 2021-08-19 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 300 | 101.00 | 30.3K | 203,000 | — | ↗ |
| 2021-08-09 | FMR LLC | Director | J-Other | D | Common Stock | 1,160,430 | 0.00 | — | 153 | — | ↗ |
| 2021-08-06 | FMR LLC | Director | J-Other | A | Common Stock | 447,236 | 0.00 | — | 1,160,583 | — | ↗ |
| 2021-07-07 | Evans John M. | Director / Officer | S-Sale | D | Common Stock | 800 | 108.65 | 86.9K | 1,036,013 | — | ↗ |
| 2021-07-06 | COOPER GRAHAM K | Director | S-Sale | D | Common Stock | 100 | 129.38 | 12.9K | 0 | — | ↗ |
| 2021-06-30 | Burrell Terry-Ann | Officer | M-Exempt | A | Common Stock | 30,000 | 13.68 | 410.4K | 54,809 | — | ↗ |
| 2021-06-30 | Burow Kristina | Director | J-Other | A | Common Stock | 2,011 | 0.00 | — | 12,067 | — | ↗ |
| 2021-06-30 | ARCH Venture Partners IX, LLC | 10% Owner | J-Other | A | Common Stock | 811 | 0.00 | — | 4,867 | — | ↗ |
| 2021-06-29 | Evans John M. | Director / Officer | J-Other | A | Common Stock | 32 | 0.00 | — | 1,021,525 | — | ↗ |
| 2021-06-29 | Burow Kristina | Director | J-Other | D | Common Stock | 200,000 | 0.00 | — | 3,121,520 | — | ↗ |
| 2021-06-29 | ARCH Venture Partners IX, LLC | 10% Owner | J-Other | A | Common Stock | 2,555 | 0.00 | — | 12,773 | — | ↗ |
| 2021-06-28 | Evans John M. | Director / Officer | L-Small | A | Common Stock | 32 | 0.00 | — | 1,021,493 | — | ↗ |
| 2021-06-28 | Ciaramella Giuseppe | Officer | S-Sale | D | Common Stock | 2,405 | 103.83 | 249.7K | 120,936 | — | ↗ |
| 2021-06-28 | COOPER GRAHAM K | Director | S-Sale | D | Common Stock | 1,000 | 109.39 | 109.4K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-92.3K
Shares Outstanding
102.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John Evans CEO | 755.0K | — | 1.51M | 2.88M | 662.5K | 10.7K | 5.82M | 75.45% | ↗ |
| 2 | 2025 | Giuseppe Ciaramella, Ph.D. President | 668.0K | — | 683.6K | 1.30M | 496.0K | 13.6K | 3.16M | 62.74% | ↗ |
| 3 | 2025 | Amy Simon, M.D. CMO | 550.0K | — | 883.6K | 1.02M | 334.1K | 13.6K | 2.80M | 67.96% | ↗ |
| 4 | 2025 | Christine Bellon, Ph.D. CLO | 510.5K | — | 390.6K | 742.4K | 310.1K | 13.6K | 1.97M | 57.59% | ↗ |
| 5 | 2025 | Sravan K. Emany CFO | 575.0K | 325.0K | — | — | 388.1K | 8.4K | 1.30M | 0.00% | ↗ |
| 6 | 2024 | John Evans CEO | 715.8K | — | 2.56M | 2.62M | 515.3K | 2.9K | 6.41M | 80.75% | ↗ |
| 7 | 2024 | Sravan K. Emany CFO | 19.9K | — | 1.98M | 2.81M | — | 50.00 | 4.82M | 99.59% | ↗ |
| 8 | 2024 | Giuseppe Ciaramella, Ph.D. President | 642.5K | — | 1.16M | 1.18M | 385.5K | 13.3K | 3.38M | 69.18% | ↗ |
| 9 | 2024 | Terry-Ann Burrell Former CFO | 321.9K | — | 1.18M | 1.26M | — | 11.1K | 2.77M | 87.97% | ↗ |
| 10 | 2024 | Amy Simon, M.D. CMO | 517.5K | — | 908.6K | 927.9K | 248.4K | 13.3K | 2.62M | 70.21% | ↗ |
| 11 | 2024 | Christine Bellon, Ph.D. CLO | 491.0K | — | 908.6K | 927.9K | 235.7K | 18.3K | 2.58M | 71.14% | ↗ |
| 12 | 2023 | John Evans CEO | 685.0K | — | 1.72M | 3.42M | 431.6K | 17.7K | 6.28M | 81.94% | ↗ |
| 13 | 2023 | Giuseppe Ciaramella, Ph.D. President | 615.0K | — | 612.4K | 1.22M | 322.9K | 17.7K | 2.79M | 65.69% | ↗ |
| 14 | 2023 | Terry-Ann Burrell Former CFO | 505.0K | — | 612.4K | 1.22M | 212.1K | 11.1K | 2.56M | 71.53% | ↗ |
| 15 | 2023 | Amy Simon, M.D. CMO | 495.0K | — | 612.4K | 1.22M | 207.9K | 12.7K | 2.55M | 71.89% | ↗ |
| 16 | 2023 | Christine Bellon, Ph.D. CLO | 470.0K | — | 535.9K | 1.07M | 197.4K | 12.7K | 2.28M | 70.19% | ↗ |
| 17 | 2022 | John Evans CEO | 650.0K | — | 3.22M | 5.16M | 448.5K | 11.8K | 9.50M | 88.31% | ↗ |
| 18 | 2022 | Giuseppe Ciaramella, Ph.D. President | 585.0K | — | 859.5K | 1.38M | 336.4K | 11.8K | 3.17M | 70.56% | ↗ |
| 19 | 2022 | Terry-Ann Burrell CFO | 480.0K | — | 859.5K | 1.38M | 220.8K | 10.4K | 2.95M | 75.87% | ↗ |
| 20 | 2022 | Terry-Ann Burrell Former CFO | 480.0K | — | 859.5K | 1.38M | 220.8K | 10.4K | 2.95M | 75.87% | ↗ |
| 21 | 2021 | John Evans CEO | 590.1K | — | 5.55M | 7.34M | 421.9K | 10.5K | 13.91M | 92.65% | ↗ |
| 22 | 2021 | Giuseppe Ciaramella, Ph.D. President and CSO | 500.0K | — | 2.00M | 2.64M | 380.3K | 10.5K | 5.54M | 83.91% | ↗ |
| 23 | 2021 | Giuseppe Ciaramella, Ph.D. President | 500.0K | — | 2.00M | 2.64M | 380.3K | 10.5K | 5.54M | 83.91% | ↗ |
| 24 | 2021 | Terry-Ann Burrell CFO | 441.0K | — | 1.40M | 1.85M | 229.3K | 17.2K | 3.94M | 82.55% | ↗ |
| 25 | 2020 | Giuseppe Ciaramella, Ph.D. President | 469.4K | — | — | 6.11M | 267.2K | 9.7K | 6.85M | 89.11% | ↗ |
| 26 | 2020 | Giuseppe Ciaramella, Ph.D. President and CSO | 469.4K | — | — | 6.11M | 267.2K | 9.7K | 6.85M | 89.11% | ↗ |
| 27 | 2020 | John Evans CEO | 529.3K | — | — | — | 367.8K | 9.7K | 906.8K | 0.00% | ↗ |
| 28 | 2020 | Terry-Ann Burrell Chief Financial Officer | 420.0K | — | — | — | 210.0K | 53.8K | 683.8K | 0.00% | ↗ |
| 29 | 2020 | Terry-Ann Burrell CFO | 420.0K | — | — | — | 210.0K | 53.8K | 683.8K | 0.00% | ↗ |
| 30 | 2019 | Terry-Ann Burrell CFO | 147.2K | — | — | 3.90M | 200.0K | 54.1K | 4.30M | 90.67% | ↗ |
| 31 | 2019 | Terry-Ann Burrell Chief Financial Officer | 147.2K | — | — | 3.90M | 200.0K | 54.1K | 4.30M | 90.67% | ↗ |
| 32 | 2019 | John Evans CEO | 472.5K | — | — | 1.37M | 367.8K | 1.0K | 2.21M | 61.93% | ↗ |
| 33 | 2019 | Giuseppe Ciaramella, Ph.D. President and CSO | 413.5K | — | — | 888.8K | 267.2K | 18.9K | 1.59M | 55.95% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Evans | Chief Executive Officer & Director | 1M | male |
| Sravan Kumar Emany | Chief Financial Officer | 1M | male |
| Giuseppe Ciaramella | President | 1M | — |
| Amy Simon | Chief Medical Officer | 897.7K | — |
| Christine Bellon | Chief Legal Officer & Corporate Secretary | 834.2K | — |
| Gopi Shanker | Chief Scientific Officer | — | — |
| J. Keith Joung | Co-Founder | — | — |
| Manmohan Singh | Chief Technology Officer | — | — |
| David R. Liu | Co-Founder | — | — |
| Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | — | female |
| Feng Zhang | Co-Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BEAM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
